Astria Therapeutics to Present at Upcoming Bradykinin Symposium
Astria Therapeutics (NASDAQ:ATXS) is set to present two posters at the Bradykinin Symposium in Berlin on September 6, 2024. The presentations focus on navenibart (STAR-0215), a potential therapy for Hereditary Angioedema (HAE).
Dr. Chris Morabito, Chief Medical Officer, will present on the ALPHA-SOLAR trial, a long-term open-label study of navenibart in HAE patients. Kusumam Joseph, Senior Director of Medical Affairs, will share updated results from the Phase 1a trial of navenibart.
These presentations highlight Astria's progress in developing treatments for allergic and immunologic diseases, particularly HAE. The symposium provides a platform for Astria to showcase its advancements in bradykinin-related therapies to the scientific community.
Astria Therapeutics (NASDAQ:ATXS) presenterà due poster al Simposio sulla Bradykinina a Berlino il 6 settembre 2024. Le presentazioni si concentrano su navenibart (STAR-0215), una potenziale terapia per l'Angioedema Ereditario (HAE).
Il Dr. Chris Morabito, Chief Medical Officer, presenterà lo studio ALPHA-SOLAR, uno studio a lungo termine in aperto su navenibart nei pazienti con HAE. Kusumam Joseph, Direttore Senior delle Questioni Mediche, condividerà risultati aggiornati dalla fase 1a dello studio di navenibart.
Queste presentazioni evidenziano i progressi di Astria nello sviluppo di trattamenti per malattie allergiche e immunologiche, in particolare HAE. Il simposio offre una piattaforma per Astria per mostrare i suoi progressi nelle terapie legate alla bradykinina alla comunità scientifica.
Astria Therapeutics (NASDAQ:ATXS) presentará dos carteles en el Simposio de Bradicina en Berlín el 6 de septiembre de 2024. Las presentaciones se centran en navenibart (STAR-0215), una terapia potencial para el Angioedema Hereditario (HAE).
El Dr. Chris Morabito, Director Médico, presentará sobre el ensayo ALPHA-SOLAR, un estudio a largo plazo abierto de navenibart en pacientes con HAE. Kusumam Joseph, Directora Senior de Asuntos Médicos, compartirá resultados actualizados del ensayo de fase 1a de navenibart.
Estas presentaciones destacan el progreso de Astria en el desarrollo de tratamientos para enfermedades alérgicas e inmunológicas, particularmente HAE. El simposio proporciona una plataforma para que Astria muestre sus avances en terapias relacionadas con la bradicinina a la comunidad científica.
Astria Therapeutics (NASDAQ:ATXS)는 2024년 9월 6일 베를린에서 열리는 브라디키닌 심포지엄에서 두 개의 포스터를 발표할 예정입니다. 발표는 나베니바르트 (STAR-0215)에 집중되며, 이는 유전성 혈관부종 (HAE)에 대한 잠재적 치료법입니다.
의학 담당 최고 책임자인 Chris Morabito 박사가 HAE 환자에서 나베니바르트를 연구한 장기 공개 시험인 ALPHA-SOLAR 연구에 대해 발표합니다. 개인의료 업무 부문 부사장인 Kusumam Joseph은 나베니바르트의 1a상 시험에서 업데이트된 결과를 공유할 것입니다.
이 발표들은 알레르기 및 면역 질환 치료법 개발에 대한 Astria의 진행 상황을 강조합니다, 특히 HAE에 대해. 심포지엄은 독일의 학계에 대한 bradykinin 관련 치료의 진전을 선보일 수 있는 플랫폼을 제공합니다.
Astria Therapeutics (NASDAQ:ATXS) présentera deux affiches lors du Symposium sur la Bradykinine à Berlin le 6 septembre 2024. Les présentations se concentrent sur navenibart (STAR-0215), une thérapie potentielle pour l'Angioedème Héréditaire (HAE).
Le Dr Chris Morabito, directeur médical, présentera l'essai ALPHA-SOLAR, une étude ouverte à long terme sur navenibart chez des patients atteints de HAE. Kusumam Joseph, directeur principal des affaires médicales, partagera les résultats actualisés de l'essai de phase 1a de navenibart.
Ces présentations mettent en évidence les progrès d'Astria dans le développement de traitements pour les maladies allergiques et immunologiques, en particulier le HAE. Le symposium offre à Astria une plateforme pour montrer ses avancées dans les thérapies liées à la bradykinine à la communauté scientifique.
Astria Therapeutics (NASDAQ:ATXS) wird am Bradykinin-Symposium in Berlin am 6. September 2024 zwei Poster präsentieren. Die Präsentationen konzentrieren sich auf navenibart (STAR-0215), eine potenzielle Therapie für hereditäres Angioödem (HAE).
Dr. Chris Morabito, Chief Medical Officer, wird über die ALPHA-SOLAR-Studie sprechen, eine langfristige offene Studie zu navenibart bei HAE-Patienten. Kusumam Joseph, Senior Director für Medizinische Angelegenheiten, wird aktualisierte Ergebnisse der Phase 1a-Studie zu navenibart vorstellen.
Diese Präsentationen heben Astrias Fortschritte bei der Entwicklung von Behandlungen für allergische und immunologische Erkrankungen, insbesondere HAE, hervor. Das Symposium bietet Astria eine Plattform, um ihre Fortschritte in den bradykininbezogenen Therapien der wissenschaftlichen Gemeinschaft zu präsentieren.
- None.
- None.
- Chris Morabito, M.D., Chief Medical Officer at Astria Therapeutics, will present information on ALPHA-SOLAR, a long-term open-label trial of navenibart (STAR-0215) in people living with HAE, in an encore presentation of a poster titled “Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215.”
- Kusumam Joseph, Senior Director of Medical Affairs at Astria Therapeutics, will present results from the Phase 1a trial of navenibart (STAR-0215) in an encore presentation of a poster titled “Phase 1a Trial of STAR-0215 for Hereditary Angioedema: Updated Results.”
Both posters will be presented at the poster session on Friday, September 6, at 3:35pm CEST.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240830515969/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
What will Astria Therapeutics present at the Bradykinin Symposium on September 6, 2024?
What is the focus of Astria Therapeutics' ALPHA-SOLAR trial?
Who will be presenting Astria Therapeutics' posters at the Bradykinin Symposium?
What is navenibart (STAR-0215) being developed for by Astria Therapeutics (ATXS)?
When and where will Astria Therapeutics (ATXS) present their posters at the Bradykinin Symposium?
